Immunotherapies for Neurologic Diseases

· Handbook of Clinical Neurology Book 214 · Elsevier
Ebook
430
Pages
Eligible
This book will become available on January 2, 2026. You will not be charged until it is released.

About this ebook

The evolution of neuroimmunotherapies with the concurrent progress in autoimmune neurology will introduce the book, followed by an update on "non-targeted" therapies highlighting the value of immunosuppressants, plasmapheresis, IVIg or hematopoietic bone marrow transplantation and their mode of action in autoimmune neurology. The new agents in each of these categories, along with biomarkers for therapeutic monitoring and the application of reliable scales in assessing response, will be covered. Chapters will discuss how neuroimmunotherapies work when key molecules and pathways associated with CNS or PNS tissue damage are targeted or inhibited. The volume will describe the approved agents targeting: 1) T-cell intracellular signaling pathways and molecules associated with antigen presentation; 2) B cells, B-cell trophic factors, and autoantibodies; 3) Fc receptor modulation; 4) complement; and 5) cytokines, cell adhesion and transmigration molecules. Didactic schemes and illustrations on how these drugs work in autoimmune neurological diseases will be provided in each chapter.The second part of the book will discuss the latest therapeutics for each major autoimmune neurological disease, aimed to provide a reliable, comprehensive and up-to-date source of information useful for clinical practice and education. Didactic and practical algorithms, a step-by step approach on how best to apply the most suitable therapies for a given state of the disease or proceed to escalation therapies will be provided.Treatment controversies and uncertainties will be authoritatively emphasized by scholars in each field. A chapter addressing potential immunotherapeutic approaches, now on the pipeline or on early trials, as future means of treating some neurodegenerative diseases will be included. Another chapter will cover the new and popular-although controversial -concept of treating autoimmune pain.The book discusses practical therapies with traditional immunosuppressants, steroids and IVIg. It describes targeted therapies with monoclonal antibodies or fusion proteins against B cells , T cells, complement, and FcRn, discussing what happens when key factors related to neurological autoimmunity are inhibited. The book provides a "how- to- do" approach for each of the major autoimmune diseases with algorithms and escalation therapies. Dedicated chapters will cover current therapies on encephalitis, NMOSD, Multiple sclerosis , autoimmune neuropathies, myopathies, neuromuscular junction disorders and neuroexcitability disorders like stiff person syndrome. The book is aimed for practitioners and academicians as a reliable and comprehensive source for applying neuroimmunotherapies and understanding their mechanisms. - Summarizes and consolidates new research on immunotherapies for neurologic diseases - Identifies how immunotherapies work - Includes monoclonal antibodies or fusion proteins against B cells , T cells, complement, and FcRn - Provides treatment algorithms and escalating therapies for common diseases - Highlights new agents in pipeline orin early trials

About the author

Dr. Marinos Dalakas is Professor of Neurology and Director of the Neuromuscular Division at Thomas Jefferson University School of Medicine in Philadelphia. He is Professor of Neurology and Chief of the Neuroimmunology Laboratory in the Department of Pathophysiology at the University of Athens Medical School in Athens, where he has been Emeritus Professor since 2016. Dr. Dalakas is an appointed member in various scientific societies and is a member of the American Neurological Association, the American Academy of Neurology, the European Neurological Society, and the International Society of Greek Neuroscientists, among other professional organizations. Dr. Dalakas has published widely. His areas of research are broad and include neuroimmunology, neurovirology, genetics, and immunotherapies in neurologic diseases. He has focused on neuropathies, myopathies, dystrophies, ALS, multiple sclerosis, and various autoimmune neurological disorders, with the application and design of new treatments. He completed a 3-year fellowship training in neuromuscular diseases at the Medical Neurology Branch of the NINCDS in Bethesda, Maryland and an additional 5-year training in Neuroimmunology/Neurovirology at NINDS. He subsequently served as Chief of the Neuromuscular Diseases Section of the NINDS, NIH, a position he held for 20 years before joining Thomas Jefferson University.

Reading information

Smartphones and tablets
Install the Google Play Books app for Android and iPad/iPhone. It syncs automatically with your account and allows you to read online or offline wherever you are.
Laptops and computers
You can listen to audiobooks purchased on Google Play using your computer's web browser.
eReaders and other devices
To read on e-ink devices like Kobo eReaders, you'll need to download a file and transfer it to your device. Follow the detailed Help Center instructions to transfer the files to supported eReaders.